ATM mutations in B-cell chronic lymphocytic leukemia.

Mutations in the ATM gene located on the long arm of chromosome 11 at 11q22-23 cause ataxia-telangiectasia, an autosomal recessive disorder that is associated with increased incidence of malignancy and, particularly, lymphoid tumors. A role for ATM in the development of sporadic T-cell chronic leukemias is supported by the finding of loss of heterozygosity at 11q22-23 and ATM mutations in leukemias carrying TCL-1 rearrangements. Approximately 14% of B-cell chronic lymphocytic leukemia (B-CLL), the most common adult leukemia, carry deletions of the long arm of chromosome 11 at 11q22-23. Loss of heterozygosity at 11q22-23 and, more recently, absence of ATM protein, have been associated with poor prognosis in B-CLL. To determine whether the ATM gene is altered in B-CLL, we have sequenced individual ATM exons in six B-CLL cases. We show that the ATM gene is mutated in a fraction of B-CLLs and that mutations can be present in the germ line of patients, suggesting that ATM heterozygotes may be predisposed to B-CLL.

[1]  E. Ostrander,et al.  Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history , 2001, Cancer.

[2]  H. Döhner,et al.  Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. , 1999, Blood.

[3]  T. Stankovic,et al.  Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia , 1999, The Lancet.

[4]  H. Kantarjian,et al.  Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. , 1998, Cancer research.

[5]  E. Stavridi,et al.  ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins , 1998, Nature Genetics.

[6]  I. Vořechovský,et al.  ATM is usually rearranged in T-cell prolymphocytic leukaemia , 1998, Oncogene.

[7]  D. Easton,et al.  ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. , 1998, American journal of human genetics.

[8]  J. Whittaker,et al.  Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival , 1997, Leukemia.

[9]  M. James,et al.  Biallelic mutations in the ATM gene in T-prolymphocytic leukemia , 1997, Nature Medicine.

[10]  M. Dyer,et al.  Clustering of missense mutations in the ataxia-telanglectasia gene in a sporadic T-cell leukaemia , 1997, Nature Genetics.

[11]  P. Leder,et al.  atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity , 1997, Nature Genetics.

[12]  M. James,et al.  11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. , 1997, Blood.

[13]  K. Isselbacher,et al.  Heterozygous ATM mutations do not contribute to early onset of breast cancer , 1997, Nature Genetics.

[14]  M. Caligiuri,et al.  Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia. , 1996, Blood.

[15]  M. James,et al.  Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Baltimore,et al.  Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. , 1996, Genes & development.

[17]  C. Croce,et al.  ATM mutations in cancer families. , 1996, Cancer research.

[18]  T. Stankovic,et al.  Mutations associated with variant phenotypes in ataxia-telangiectasia. , 1996, American journal of human genetics.

[19]  Francis Collins,et al.  Atm-Deficient Mice: A Paradigm of Ataxia Telangiectasia , 1996, Cell.

[20]  M. James,et al.  The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. , 1996, Cancer research.

[21]  A. Taylor,et al.  Leukemia and lymphoma in ataxia telangiectasia. , 1996, Blood.

[22]  C. Croce,et al.  Genomic organization of the ATM locus involved in ataxia-telangiectasia. , 1995, Cancer research.

[23]  C. Fegan,et al.  Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. , 1995, Leukemia.

[24]  F. Collins,et al.  The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. , 1995, Human molecular genetics.

[25]  M. Isobe,et al.  TCL1 oncogene activation in preleukemic T cells from a case of ataxia-telangiectasia. , 1995, Blood.

[26]  V. Zakian.  ATM-related genes: What do they tell us about functions of the human gene? , 1995, Cell.

[27]  P. Nowell,et al.  Clinical heterogeneity reflects biologic diversity in chronic lymphocytic leukemia. , 1995, Critical reviews in oncology/hematology.

[28]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.

[29]  M. Isobe,et al.  Identification of the TCL1 gene involved in T-cell malignancies. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  F. Sigaux,et al.  MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. , 1993, Oncogene.

[31]  L. Hammarström,et al.  [Ataxia-telangiectasia surveyed in Sweden]. , 2000, Lakartidningen.

[32]  K. Kaushansky,et al.  A new year greeting from a new editor , 1998, Blood.

[33]  D. Easton.  Cancer Risks in A-T Heterozygotes. , 1994, International journal of radiation biology.

[34]  P. Sherrington,et al.  VH gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia , 2022 .